Bioinformatic identification and experiment validation revealed that ACTG1 is a promising prognostic signature and therapeutic target for sepsis

J Leukoc Biol. 2023 Sep 27;114(4):325-334. doi: 10.1093/jleuko/qiad072.

Abstract

In the intensive care unit, sepsis is a prevalent clinical syndrome (i.e. the final pathway to death from most infections). Peripheral blood gene expression profiling is becoming more and more accepted as a potential diagnostic or prognostic tool. This work aimed to recognize genes related to sepsis, providing potential translational therapeutic targets. RNA sequencing was performed on peripheral blood mononuclear cells from 20 healthy control subjects and 51 sepsis patients. Weighted gene coexpression network analysis was employed to pick out sepsis-related and immunocyte-related gene modules. Genes in the yellow module are primarily involved in excessive inflammation and immune suppression. STRING and Cytoscape were combined to identify ACTG1 and IQGAP1 as hub genes with highest connective degree, and prognostic predication value of ACTG1 was confirmed. Both univariate and multivariate logistic regression analyses were carried out. ACTG1 messenger RNA expression was increased in animal and in cell-related sepsis models. Small interfering RNA revealed decreasing ACTG1 can reduce the in vitro sepsis model apoptosis. We have authenticated ACTG1 as a reliable signature of a poor outcome of sepsis and promising therapeutic targets for sepsis.

Keywords: ACTG1; RNA-Seq; bioinformatics; biomarker; sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins
  • Animals
  • Apoptosis / genetics
  • Computational Biology
  • Gene Expression Profiling
  • Humans
  • Leukocytes, Mononuclear*
  • Prognosis
  • Sepsis* / diagnosis
  • Sepsis* / genetics

Substances

  • ACTG1 protein, human
  • Actins